Physician profile
Katie Mccool
NPI 1811614670
$2,614.83
in general payments reported to CMS, 2019-2025
14 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $79.06 · 2023: $401 · 2024: $435 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $606.10 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $518.75 | 2023-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $267.58 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $245.76 | 2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.05 | 2025 | Jardiance |
| Silk Road Medical, INC. | $127.29 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.78 | 2023 | |
| Astellas Pharma US INC | $112.12 | 2023 | Veozah |
| Cequr Corporation | $107.18 | 2025 | Cequr Simplicity |
| Pfizer INC. | $96.03 | 2025 | |
| Lilly USA, LLC | $93.56 | 2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $79.06 | 2022 | |
| Neurelis, INC. | $74.81 | 2024 | Valtoco |
| Glaxosmithkline, LLC. | $15.76 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Mccool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.